KeywordsBifidobacterium bifidum; aptamer; SELEX; sequence truncation; colorimetric bioassay; prion protein; nucleic acids; SELEX (Systematic Evolution of Ligands by Exponential Enrichment); aptamers; nucleic acid aptamer; nuclease degradation; rapid excretion; binding affinity; chemical modification; aptamer; DNA damage; DNA repair; in vitro selection; SELEX; mutation; therapeutics; aptamers; systematic evolution of ligands by exponential enrichment (SELEX); modified triphosphates; medical imaging; drug delivery; gene regulation; DNA origami; neurodegenerative diseases; riboswitch; aptamer; mRNA structure; gene regulation; aptamer; staphylococcal protein A; label-free; biosensing techniques; rapid detection; self-assembly; limit of detection; protein binding; ferri-/ferrocyanide; gold electrode; aptamer; simulation; in silico selection; molecular dynamics; fragment based design; HTS; glioblastoma; aptamers; SELEX; cancer; targeted therapies; imaging; diagnosis; biomarkers; blood brain barrier; aptamers; charomers; targeted drug delivery; targeted chemotherapy; photodynamic therapy; interleukin-6 receptor; light-up aptamer; fluorogen; fluorogenic dye; fluorescence; RNA; in vitro evolution; gene expression monitoring; live-cell imaging; biosensing; SELEX; in vitro selection; aptamer; molecular recognition element (MRE); fipronil; pesticide; insecticide; ELISA; Decoy-SELEX; SELEX; aptamers; design of nucleic acid libraries; Alzheimer disease; amyloid β-protein; antibodies; cross-reactions; nucleotide aptamers; oligonucleotide ligands; systematic evolution of ligands by exponential enrichment; specificity; therapeutics; aptamer; SELEX; ubiquitin ligase; WWP1; targeted drug delivery
